The US FDA has approved generic liraglutide injection from Israel’s Teva. It copies Novo Nordisk’s obesity drug Saxenda, which costs over $1,300 per month. Liraglutide mimics the body’s glucagon-like peptide-1 hormone, suppressing appetite and triggering insulin release for up to 24 hours.

https://jewishbreakingnews.com/teva-wins-fda-approval-for-first-generic-weight-loss-drug/